Relative to docetaxel, and especially in NSCLC patients without oncogenic driver mutations or translocations, superior overall survival (OS) and progression‐free survival (PFS) are associated with second‐line ICI treatment using nivolumab1, 2 and pembrolizumab,3 which target programmed cell death‐1 (PD‐1), as well as atezolizumab,4 which targets programmed death ligand 1 (PD‐L1). The gene discussed is CD274; the disease is non-small cell lung carcinoma.